Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Mylan and Lupin Announce Positive CHMP Opinion for Nepexto Biosimilar Etanercept
The CHMP positive opinion will now be considered by the European Commission (EC). Once approved the EC will grant a centralized marketing authorization for member countries of the EU. The decision on the EC's approval is expected in May 2020.

Mylan N.V and Lupin Limited (Lupin) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto, a biosimilar to Enbrel (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

The positive CHMP opinion is based on a biosimilarity assessment which included preclinical and clinical studies demonstrating bioequivalence to the reference product. In addition, a phase 3 clinical studyi in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety and immunogenicity.

The CHMP positive opinion will now be considered by the European Commission (EC). Once approved the EC will grant a centralized marketing authorization for member countries of the EU. The decision on the EC's approval is expected in May 2020.

Mylan President Mr Rajiv Malik commented, "We are pleased with the positive CHMP opinion for Nepexto, biosimilar etanercept. This recommendation validates the strong scientific program supporting this important treatment, which is one of 20 products in our broad and diverse biosimilars portfolio, and our shared commitment with Lupin to help increase access to more affordable biologic treatments, such as etanercept, in Europe and many other regions around the world."

Vinita Gupta, CEO, Lupin Limited said, "Biosimilars like Nepexto will play a critical role in expanding access to patients in Europe, providing an effective treatment for multiple therapies including rheumatoid arthritis. We are extremely pleased with the positive CHMP opinion on our application. This milestone brings us one step closer to bringing an affordable biosimilar to etanercept to the European market through our partner Mylan. Once approved by the European Commission, Nepexto will be our first biosimilar to receive regulatory approval in Europe. Building on this progress, we continue to focus on advancing our biosimilar pipeline."

Enbrel had sales of approximately $9.6 billion globally for the 12 months ending December 2019, accord

Tags : #Mylannv #Lupinlabs #Nepexto #Etanercept

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Flight to Nowhere: The Air India Crash That Shook Ahmedabad and Raised Global Safety AlarmsJune 13, 2025
She Went for Pain Relief, Came Back With a Torn Artery: A Chiropractic Horror StoryJune 13, 2025
Biology vs Burnout: What Night Shifts Are Really Doing to Your Brain and BodyJune 13, 2025
Renowned Gynaecologist Joins Manipal Hospital Gurugram to Strengthen Women’s HealthJune 13, 2025
Aster CMI Hospital Saves Young Woman from Limb Loss in Rare Vascular SurgeryJune 13, 2025
QNET Unveils Father’s Day Gifts to Honour the Everyday Hero in Your LifeJune 13, 2025
Manipal Hospital Ghaziabad becomes first in the city to perform REZUM to treat prostate enlargementJune 13, 2025
Gen Z Doctors: Rethinking the White Coat Culture in IndiaJune 13, 2025
How Menopause Is Finally Becoming a Mainstream Medical ConversationJune 13, 2025
Thinner Bodies, Heavier Minds: When Diets Damage Mental HealthJune 13, 2025
Unite Health systems with Community-led health services to deliver on UHCJune 12, 2025
SIMS Hospital Performs India’s First Combined Open-Heart Valve Replacement and TAVR Valve-Specialised Aortic Graft SurgeryJune 12, 2025
Sodexo Partners with Medanta, Indore to Enhance Patient Dining ExperienceJune 12, 2025
University of Leeds invites applications for MSc in Air Quality Solutions with Data ScienceJune 12, 2025
IPV Leads Iom Bioworks ₹4 Cr in Seed Round to Revolutionize Healthcare Through Gut Microbiome ScienceJune 12, 2025
Rural Telehealth Fatigue: Is Screen-Based Healthcare Reaching Saturation?June 12, 2025
Medical Misinformation in the Age of Instagram: A Doctor’s DilemmaJune 12, 2025
Integrating Ayurvedic Principles into Modern Chronic Disease ManagementJune 12, 2025
Patient with multiple life-threatening conditions saved after rare, high-risk heart surgeryJune 11, 2025
Clove Oral Care Launches Its Toothpaste and Toothbrush Range, specially designed for Indian MouthsJune 11, 2025